Orphan drugs policies: a suitable case for treatment (Q38179281)

30 August 2017

Orphan drugs policies: a suitable case for treatment (English)

1 reference

30 August 2017

1 reference

Michael Drummond

1

1 reference

PubMed ID

24435513

30 August 2017

Adrian Towse

series ordinal

2

1 reference

30 August 2017

1 May 2014

1 reference

The European Journal of Health Economics

30 August 2017

1 reference

30 August 2017

15

1 reference

30 August 2017

335-340

1 reference

30 August 2017

4

1 reference

https://scigraph.springernature.com/pub.10.1007/s10198-014-0560-1

30 August 2017

0 references

cites work

Orphan drugs: the regulatory environment

1 reference

https://api.crossref.org/works/10.1007%2FS10198-014-0560-1

Orphan drugs and the NHS: should we value rarity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-014-0560-1

Societal views on NICE, cancer drugs fund and value-based pricing criteria for prioritising medicines: a cross-sectional survey of 4118 adults in Great Britain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-014-0560-1

Societal views on orphan drugs: cross sectional survey of Norwegians aged 40 to 67

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-014-0560-1

Conjoint analysis applications in health--a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-014-0560-1

Orphan drug development: an economically viable strategy for biopharma R&D.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-014-0560-1

What is wrong with orphan drug policies? Suggestions for ways forward.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-014-0560-1

An evaluation framework for funding drugs for rare diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-014-0560-1

Is the current approach to reviewing new drugs condemning the victims of rare diseases to death? A call for a national orphan drug review policy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-014-0560-1

Economic evaluations in the canadian common drug review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-014-0560-1

Challenges in the development and reimbursement of personalized medicine-payer and manufacturer perspectives and implications for health economics and outcomes research: a report of the ISPOR personalized medicine special interest group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-014-0560-1

The Health Impact Fund: incentives for improving access to medicines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-014-0560-1

A breakthrough in R&D; for neglected diseases: new ways to get the drugs we need

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-014-0560-1

Advance market commitments for vaccines against neglected diseases: estimating costs and effectiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-014-0560-1

The trade-off between severity of illness and treatment effect in cost-value analysis of health care

21 January 2018

1 reference

12 December 2020

Is quantitative benefit-risk modelling of drugs desirable or possible?

1 reference

12 December 2020

Is it time to revisit orphan drug policies?

1 reference

12 December 2020

Key principles for the improved conduct of health technology assessments for resource allocation decisions

1 reference

12 December 2020

Assessing the economic challenges posed by orphan drugs

1 reference

12 December 2020

Need: the idea won't do--but we still need it

1 reference

12 December 2020

What is wrong with orphan drug policies?

1 reference

12 December 2020

10.1007/S10198-014-0560-1

Identifiers

DOI

1 reference

30 August 2017

1 reference

PubMed ID

24435513